Investor Relations
THE SHARE: Change: -0.20 SEK (-0.97%) / Price: 20.45 SEK / Nov 11, 2025, 9:05 am (CET)
Press Releases
October 17, 2025 08:30 (CEST)
Genovis receives order worth approximately 1 million euros from global pharmaceutical company
Regulatory
MAR
July 24, 2025 08:30 (CEST)
Genovis Expands License Agreement to Access Proprietary Enzyme Technology for Therapeutic Antibody-Drug Conjugate Development
July 01, 2025 18:00 (CEST)
Genovis Exercises Call Option to Acquire Remaining Shares in SEQURNA, a fast-growing next-generation RNase inhibitors company
Regulatory
MAR
Financial Reports
Financial Calendar
- Q4 2025
February 12, 2026 - Q1 2026
April 28, 2026 - Q2 2026
July 23, 2026 - Q3 2026
November 10, 2026
